Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

Company Overview - Agios Pharmaceuticals is a leader in cellular metabolism and PK activation, focusing on therapies for rare diseases [2] - The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, which is the first disease-modifying therapy for this condition [2] - Agios is advancing a clinical pipeline that includes investigational medicines for alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia, and phenylketonuria (PKU) [2] - Additionally, Agios is developing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera [2] Upcoming Events - Agios Pharmaceuticals is scheduled to present at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024, at 8:00 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay archived for at least two weeks [1]